Cystic Fibrosis Therapeutics Market is set to Grow at a Remarkable Pace by 2033
In 2023, the global Cystic Fibrosis Therapeutics Market is expected to be worth US$ 12.5 billion. The overall demand for Cystic Fibrosis is expected to grow at a CAGR of 25.0% between 2023 and 2033, totaling around US$ 116.42 Billion by 2033, with the implementation of innovative treatment options for early detection.
The rising prevalence
of CF indicates an increase in demand for treatment options, which will drive
the Cystic Fibrosis Therapeutics Market in the near future. The key players in
this market focus on the development of novel therapeutics for treatment in
collaboration with nonprofit organisations. VX-445 + tezacaftor + ivacaftor,
PTI-428, QR-010, AZD5634, and POL6014 are among the drugs in clinical trials.
The rising prevalence
of cystic fibrosis, advancements in screening and treatment, and the
availability of modified drug therapy and molecular prosthetics to cure cystic
fibrosis are the major factors driving the revenue share of the cystic fibrosis
therapeutics market during the forecast period. Furthermore, rising awareness
about this progressive genetic disease, as well as the increasing adoption of
drug therapies, are important factors that are expected to accelerate market
growth over the forecast period.
Competitive
Landscape
Prominent players
in the Cystic Fibrosis Therapeutics Market are Novartis AG, Vertex Pharmaceuticals Incorporated,
AbbVie Inc., Gilead Sciences, Inc., Mylan N.V., Pfizer Inc., Bayer AG,
Genentech, Inc., and AstraZeneca, among others.
Recent
Developments:
- In April 2018, Novartis Venture Fund along with
Versant Ventures invested US$ 41 million for series B round in cystic
fibrosis disease startup Enterprise Therapeutics. The financing will allow
Enterprise Therapeutics to push three projects into clinical phase.
- In March 2018, US FDA approved product
named Symdeko manufactured by Vertex Pharmaceuticals Incorporated. The
product is a combination of Tezacaftor and Ivacaftor majorly used in the
treatment of CF.
Read
More Details@ https://www.futuremarketinsights.com/reports/cystic-fibrosis-therapeutics-market
Key
Segments Covered in the Cystic Fibrosis Industry Analysis
Cystic
Fibrosis Therapeutics Market by Drug Class:
- Cystic
Fibrosis Transmembrane Conductance Regulator (CFTR)
- Bronchodilators
- Mucolytic
- Pancreatic
Enzyme Supplement
- Others
Cystic
Fibrosis Therapeutics Market by Route of Administration:
- Oral
- Parenteral
Cystic
Fibrosis Therapeutics Market by Distribution Channel:
- Retail
Pharmacies & Drug Stores
- Online
Pharmacies
- Hospital
Pharmacies
Comments
Post a Comment